Fig. 2.

Development and validation of the miGISig in prognostic risk stratification. Kaplan–Meier estimates of OS or DRFS of patients with low or high miGISig score in the discovery cohort (a), internal testing cohort (b) and GSE22220 cohort (c). HRs and 95% CIs for high vs. low miGISig score were estimated using the univariate Cox analysis. P values comparing risk groups were calculated with the log-rank test. Violin diagram of CSPM burden and aneuploidy scores in the low risk group and high risk group in TCGA-BC cohort (d) and in the GS-like group and GU-like group in TCGA-OV cohort (e). Statistical analysis was performed using the Mann–Whitney U test. *P-value < 0.05, **P-value < 0.01, ***P-value < 0.001. BC breast cancer, CIs confidence intervals, CSPM cumulative somatic point mutation, DRFS Distant relapse-free survival, GI Genome instability, GS genomically stable, GU genomically unstable, HRs Hazard ratios, OS overall survival